The Ahmedabad-based drug maker will submit the outcomes of its phase-2 trials next week, which “will determine the safety, dosage and efficacy of the potential vaccine”, stated the individual who requested not to be determined.
Find Out More
The Ahmedabad-based drug maker will submit the outcomes of its phase-2 trials next week, which “will determine the safety, dosage and efficacy of the potential vaccine”, stated the individual who requested not to be determined.
Find Out More